Navigation Links
Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
Date:11/18/2013

Irvine, CA - (PRWEB) November 18, 2013

Proove Biosciences, the leading personalized pain medicine laboratory, will be exhibiting and presenting clinical data and research at the National Workers’ Compensation and Disability Conference Expo. This industry-leading event attracts thousands of workers’ compensation and disability management professionals from around the country, and will be hosted at the Mandalay Bay Hotel, in Las Vegas November 20-22, 2013.

The NWCD Conference allows professionals to receive guidance and insight on new trends from experts spanning all spectrum of the industry. This year’s event will contain a brand new track on disability management solutions, sessions devoted to critical issues in trendsetting states which typically affect associated regions, and an emphasis on technology, innovation and research.

Proove Biosciences has been presenting research and findings at pain medicine scientific meetings across the country in 2013, and will now have the opportunity to present to the case managers, claims managers, health and safety professionals, legislators, and other workers compensation and disability claims personnel in attendance. This year’s emphasis on technology and innovation aligns perfectly with Proove’s mission and capacity in delivering scientific proof towards reducing costs and improving outcomes of workers compensation claims.

“Workers compensation and disability claims are a huge cost driver in this industry, in larger part because of medical abuse and dependence that stems from a gap in understanding a patient's individual genetic profile,” stated Proove Biosciences President and Founder, Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine, and the only company with data specifically on genetics and pain medicine. We are happy and excited to exhibit our work at the NWCD and help inform professionals on how we can all lower risk, costs, and improve patient and worker health.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/11/prweb11333081.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)... Jan. 18, 2017   Parent Project Muscular Dystrophy ... end Duchenne muscular dystrophy (Duchenne) , today announced ... Jersey Institute of Technology (NJIT) and Talem Technologies (Talem) ... robotic technology to assist people living with Duchenne. ... technology – an embedded computer, software, a force sensor ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place ... in Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has ... (NIIMBL), and the Department of Defense has announced the award of a new ...
Breaking Biology Technology:
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
Breaking Biology News(10 mins):